
-
Immunocore Holdings NasdaqGS:IMCR Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Location: 92 Park Drive, Abingdon, OX14 4RY, United Kingdom | Website: https://www.immunocore.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.357B
Cash
837M
Avg Qtr Burn
N/A
Short % of Float
21.25%
Insider Ownership
5.18%
Institutional Own.
97.43%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KIMMTRAK (Tebentafusp) (gp100) Details Metastatic uveal melanoma, Melanoma, Cancer | Approved Quarterly sales | |
KIMMTRAK (Tebentafusp) (gp100) Details Metastatic uveal melanoma, Cancer, Melanoma | Phase 3 Data readout | |
KIMMTRAK (Tebentafusp) +/- anti-PD1 Details Cancer, Melanoma | Phase 3 Data readout | |
IMC-F106C (Brenetafusp) + nivolumab Details Cancer, Melanoma | Phase 3 Update | |
IMC-R117C [PIWIL1-A02 targeted] Details Cancer, Colorectal cancer , Gastrointestinal stromal tumors | Phase 1/2 Data readout | |
IMC-F106C (Brenetafusp) Details Ovarian cancer, Solid tumor/s, Cancer, Breast cancer, Endometrial cancer | Phase 1/2 Data readout | |
IMC-M113V (Gag-A02) Details Viral infection, Human immunodeficiency virus | Phase 1/2 Update | |
IMC-F106C (Brenetafusp) +/- Pembrolizumab Details Cancer, Melanoma | Phase 1/2 Update | |
IMC-P115C (PRAME-HLE-A02) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
IMC-I109V Details Viral infection, Hepatocellular carcinoma, Hepatitis B | Phase 1 Data readout | |
IMC-C103C Details Ovarian cancer, Head and neck cancer, Cancer, Non-small cell lung carcinoma, Gastric cancer, Solid tumor/s | Phase 1 Update | |
IMC-U120AI Details Atopic dermatitis | IND Submission | |
IMC-S118AI Details Type 1 Diabetes | IND Submission |